Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax, Ixazomib Citrate, and Dexamethasone in Relapsed/Refractory Light Chain Amyloidosis
NCT04847453Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Aug 2022
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of venetoclax in light-chain amyloidosis, sponsored by National Cancer Institute. Primary endpoints: Incidence of adverse events at 30 days, Maximum tolerated dose and 1 more. Started Aug 2022; status: active, not recruiting.
02
Drugs
venetoclax
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on NCT04847453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04847453.